Response Versus Remission in Obsessive-Compulsive Disorder
The DOI matches its Crossref record.
Abstract
Article Abstract Objective: To investigate rates of response and remission in adults with obsessive-compulsive disorder (OCD) after 12 weeks of evidence-based treatment. Method: Post hoc analyses of response and remission were conducted using data from a multisite, randomized, controlled trial comparing the effects of 12 weeks of exposure and ritual prevention (EX/RP), clomipramine (CMI), their combination (EX/RP+CMI), or pill placebo (PBO) in 122 adults with OCD (DSM-III-R or DSM-IV criteria). Response was defined as a decrease in symptoms; remission was defined as minimal symptoms after treatment. Different response and remission definitions were constructed based on criteria used in prior studies. For each definition, the proportion of responders or remitters in each treatment group was then compared. Results: There were significant differences (p < .05) among the 4 treatment groups in the proportion of responders and remitters. In pairwise comparisons, EX/RP + CMI and EX/RP each produced significantly more responders and remitters than PBO; CMI produced significantly more responders and remitters than PBO for some definitions but not for others. When remission was defined as a Yale-Brown Obsessive Compulsive Scale (YBOCS) score of 12 or less, significantly more EX/RP + CMI (18/31 ) and EX/RP (15/29 ) patients entering treatment achieved remission than either CMI (9/36 ) or PBO (0/26 ) patients. However, even in treatment completers, many CMI and some EX/RP + CMI and EX/RP patients did not achieve remission (remission rates for YBOCS < = 12: EX/RP + CMI = 13/19 ; EX/RP = 15/21 ; CMI = 8/27 ; PBO = 0/20 ). Conclusion: EX/RP (with or without CMI) can lead to superior treatment outcome compared with CMI alone in OCD patients without comorbid depression. However, many OCD patients who receive evidence-based treatment do not achieve remission.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“exposure and response prevention (ERP), which is now considered to be the first-line psychotherapy for the disorder.”
From Exposure and response prevention for obsessive-compulsive disorder: A review and new directions (2019) · cites this paper as [26]
In the citing paper
“only about half of the patients who receive it will reach complete symptom remission.[26]”
From Exposure and response prevention for obsessive-compulsive disorder: A review and new directions (2019) · cites this paper as [26]
In the citing paper
“EX/RP typically helps up to half of patients achieve minimal symptoms after treatment (i.e., remission) (12).”
From Task-based fMRI predicts response and remission to exposure therapy in obsessive-compulsive disorder (2019) · cites this paper as [12]
In the citing paper
“this cutoff not only reflects minimal symptoms after treatment but also predicts good quality of life and adaptive functioning (12,26,30).”
From Task-based fMRI predicts response and remission to exposure therapy in obsessive-compulsive disorder (2019) · cites this paper as [12]
In the citing paper
“operationalized as a posttreatment Y-BOCS score ≤ 12, given that this cutoff reflects symptom reduction and predicts good quality of life and adaptive functioning (12,26,30).”
From Task-based fMRI predicts response and remission to exposure therapy in obsessive-compulsive disorder (2019) · cites this paper as [12]
Citations
Cited by
Items 101–200 of 239
Internet administration of the Dimensional Obsessive-Compulsive Scale: a psychometric evaluation
Enander, J., Andersson, E., Kaldo, V., Lindefors, N., Andersson, G., & Rück, C. (2012) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2012.07.008 · Cited by 27
Management of Treatment-Resistant Obsessive-Compulsive Disorder
Gershkovich, M., Wheaton, M. G., & Simpson, H. B. (2017) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-017-0127-8 · Cited by 32
Self-citationLandmann, S., Cludius, B., Tuschen‐Caffier, B., Moritz, S., & Külz, A. K. (2019) · Behaviour Research and Therapy · doi:10.1016/j.brat.2019.103449 · Cited by 32
Yoosefee, S., Amanat, M., Salehi, M., Mousavi, S. V., Behzadmanesh, J., Safary, V., Yoonesi, A., & Salehi, B. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02979-1 · Cited by 33
Innovations in the delivery of exposure and response prevention for obsessive-compulsive disorder
Patel, S. R., Comer, J., & Simpson, H. B. (2021) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2020_202 · Cited by 24
Self-citationLandmann, S., Cludius, B., Tuschen‐Caffier, B., Moritz, S., & Külz, A. K. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112842 · Cited by 28
Prazeres, A. M., de Souza, W. F., & Fontenelle, L. F. (2007) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462006005000046 · Cited by 61
Deep brain stimulation for obsessive compulsive disorder: A review of results by anatomical target
Borders, C. B., Hsu, F. P. K., Sweidan, A. J., Matei, E. S., & Bota, R. G. (2018) · Mental Illness · doi:10.4081/mi.2018.7900 · Cited by 36
Sookman, D., Phillips, K. A., Anholt, G. E., Bhar, S. S., Bream, V., Challacombe, F. L., Coughtrey, A. E., Craske, M. G., Foa, E. B., Gagné, J.-P., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113752 · Cited by 24
Self-citationMarazziti, D., Mungai, F., Másala, I., Baroni, S., Vivarelli, L., Ambrogi, F., Dell’Osso, M. C., Consoli, G., Massimetti, G., & Dell’Osso, L. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108089605 · Cited by 24
The mental health clinic: a new model
Fava, G. A., PARK, S. K., & Dubovsky, S. L. (2008) · World Psychiatry · doi:10.1002/j.2051-5545.2008.tb00192.x · Cited by 27
“World Psychiatry 7:3 - October 2008 178 complete remission of symptoms and restoration of normal function is not frequent in such psychiatric disorders as major depression (13), panic disorder (14), obsessive-compulsive disorder (15), eating disorders (16) and schizophrenia (17).”
BackgroundHiranandani, S., Ipek, S. I., Wilhelm, S., & Greenberg, J. L. (2023) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2022.100765 · Cited by 24
McLean, C. P., Zandberg, L. J., Meter, P. E. V., Carpenter, J. K., Simpson, H. B., & Foa, E. B. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09513 · Cited by 25
Self-citationShi, T. C., Pagliaccio, D., Cyr, M., Simpson, H. B., & Marsh, R. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00929-9 · Cited by 25
Self-citationStarčević, V. (2014) · Current Psychiatry Reviews · doi:10.2174/1573400509666131119011010 · Cited by 24
“Patients with hypochondriasis were also reported to exhibit a higher placebo response rate (33%) [50] than those with OCD (10%) [52, 53].”
BackgroundTreatment Resistance in Obsessive-Compulsive Disorder
Middleton, R., Wheaton, M. G., Kayser, R., & Simpson, H. B. (2019) · Treatment Resistance in Psychiatry · doi:10.1007/978-981-10-4358-1_11 · Cited by 19
Self-citationJahanbakhsh, G., Javadi, S. A. H. S., Majidi, M., Khademi, M., & Karimi, R. (2022) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2022.103384 · Cited by 24
What Can Motivational Interviewing Do for You?
Burke, B. L. (2010) · Cognitive and Behavioral Practice · doi:10.1016/j.cbpra.2009.08.004 · Cited by 24
Murphy, D., Glaser, K., Hayward, H., Eklund, H., Cadman, T., Findon, J., Woodhouse, E., Ashwood, K., Beecham, J., Bolton, P., et al. (2018) · Programme Grants for Applied Research · doi:10.3310/pgfar06020 · Cited by 18
“A reduction of at least 25% on the YBOCS severity rating scale is considered to be a sensitive but not specific measure of treatment response.(352) A YBOCS total score of ≤ 12 for ≥ 1 week was used to define remission,(352) with remission lasting for ≥ 1 month being defined as recovery.”
MethodLeichsenring, F., & Steinert, C. (2017) · Bulletin of the Menninger Clinic · doi:10.1521/bumc_2017_81_07 · Cited by 25
da Silva, R. D. M. F., Batistuzzo, M. C., Shavitt, R. G., Miguel, E. C., Stern, E. R., Mezger, E., Padberg, F., D’Urso, G., & Brunoni, A. R. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1637257 · Cited by 20
“Nonetheless, up to one third of patients fail to respond adequately to first-line therapies [4].”
BackgroundSpecialized cognitive behavior therapy for treatment resistant obsessive compulsive disorder.
Sookman, D., & Steketee, G. S. (2009) · Cited by 15
The prefrontal cortex and neurosurgical treatment for intractable OCD
Rasmussen, S. A., & Goodman, W. K. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01149-5 · Cited by 19
“Approximately 30–40% of patients fail to respond to either modality [12, 13], few patients experience complete symptom resolution [14], up to 25% of patients have difficulty tolerating CBT [15], and the risk of relapse after therapies remains significant.”
BackgroundPatel, S. R., Galfalvy, H., Kimeldorf, M. B., Dixon, L. B., & Simpson, H. B. (2016) · Psychiatric Services · doi:10.1176/appi.ps.201600092 · Cited by 18
“Persons experiencing residual symptoms while taking SRI medications may augment response with EX/RP or antipsychotic medications (17).”
BackgroundSelf-citationPagliaccio, D., Cha, J., He, X., Cyr, M., Yanes-Lukin, P. K., Goldberg, P. H., Fontaine, M., Rynn, M. A., & Marsh, R. (2019) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13191 · Cited by 30
“CBT “responders” were defined by a posttreatment CY-BOCS≤12, given prior work (Simpson et al., 2006).”
MethodZhang, T., Lu, L., Didonna, F., Wang, Z., Zhang, H., & Fan, Q. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.661807 · Cited by 27
“Inclusion criteria: (1) Male or female OCD patients aged 18–54 years who were diagnosed by a Chinese version of the Mini-International Neuropsychiatric Interview [MINI] for DSM-5 with mild and moderate level of OCD symptoms, which means Y-BOCS score ranging from 12 to 25 grades (27); (2) Junior/middle school education…”
MethodKatz, D. E., Rector, N. A., McCabe, R. E., Hawley, L. L., Rowa, K., Richter, M. A., Ornstein, T. J., Regev, R., McKinnon, M. C., & Laposa, J. M. (2023) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2023.102746 · Cited by 17
Tjelle, K., Opstad, H. B., Solem, S., Kvale, G., Wheaton, M. G., Björgvinsson, Þ., Hansen, B. K. A., & Hagen, K. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05780-6 · Cited by 17
“%) experience a treatment response (25–35% decrease in symptoms), usually fewer than half achieve remission (minimal symptoms after treatment [Yale-Brown Obsessive Compulsive Scale scores below 16, 12, or 7]) [14].”
BackgroundTreating refractory obsessive-compulsive disorder: what to do when conventional treatment fails?
Franz, A. P., Paim, M. F., de Araújo, R. M. F., Rosa, V. D. O., Barbosa, Í. M., Blaya, C., & Ferrão, Y. A. (2013) · Trends in Psychiatry and Psychotherapy · doi:10.1590/s2237-60892013000100004 · Cited by 17
Sguazzin, C. M. G., Key, B. L., Rowa, K., Bieling, P. J., & McCabe, R. E. (2017) · Mindfulness · doi:10.1007/s12671-016-0592-y · Cited by 15
“However, many patients continue to experience residual symptoms after CBT (Franklin and Foa 2008; Simpson et al. 2006; Stanley and Turner 1996).”
BackgroundNeal, R. L., & Radomsky, A. S. (2019) · Cognitive Therapy and Research · doi:10.1007/s10608-019-10007-0 · Cited by 19
Predictors of treatment outcome in OCD: An interpersonal perspective
Tibi, L., van Oppen, P., van Balkom, A. J. L. M., Eikelenboom, M., Emmelkamp, P. M. G., & Anholt, G. E. (2019) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2019.102153 · Cited by 19
Kreiss, D. S., Coffman, C. F., Fiacco, N. R., Granger, J. C., Helton, B. M., Jackson, J. C., Kim, L. V., Mistry, R. S., Mizer, T. M., Palmer, L. V., et al. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.01.006 · Cited by 16
Bolu, A., Gündoğmuş, İ., Aydın, M. S., Fadıloğlu, D., Erken, Y., & Uzun, Ö. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113986 · Cited by 16
High-Dose Duloxetine for Treatment-Resistant Obsessive-Compulsive Disorder
Yeh, Y., Chen, C., Kuo, S.-C., Wang, S.-C., Chen, C.-K., & Feng, H.-M. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31817f8cef · Cited by 14
Pharmacotherapy for obsessive—compulsive disorder
Fineberg, N. A., & Brown, A. (2011) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.109.007237 · Cited by 15
“Simpson et al (2006) demonstrated that a Y-BOCS score of 7 could not differentiate between active and control treatments.”
BackgroundDavis, R. A., Winston, H. R., Gault, J., Kern, D. S., Mikulich‐Gilbertson, S. K., & Abosch, A. (2021) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.20060153 · Cited by 14
Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder
Harmelech, T., Roth, Y., & Tendler, A. (2022) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.10.003 · Cited by 17
Kuty-Pachecka, M. (2021) · Psychiatria Polska · doi:10.12740/pp/112051 · Cited by 18
Electroconvulsive therapy for obsessive-compulsive disorder: A retrospective study
Li, K., Long, J., Deng, W., Cheng, B., & Wang, J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1040443 · Cited by 16
Sookman, D., Phillips, K. A., Mataix‐Cols, D., & Veale, D. M. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113753 · Cited by 13
Mancebo, M. C., Yip, A. G., Boisseau, C. L., Rasmussen, S. A., & Zlotnick, C. (2021) · Behavior Therapy · doi:10.1016/j.beth.2021.02.009 · Cited by 12
Gregory, S. T., Goodman, W. K., Kay, B., Riemann, B. C., & Storch, E. A. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.12.034 · Cited by 16
Alić, M., de Leeuw, A., Selier, J., van Megen, H. J. G. M., & Visser, H. A. D. (2022) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.2715 · Cited by 14
Chou, P., Sack, A. T., & Su, K. (2022) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2022.20.4.773 · Cited by 13
da Silva, R. D. M. F., Brunoni, A. R., Miguel, E. C., & Shavitt, R. G. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s184839 · Cited by 15
“Therefore, about one-third of the patients remain symptomatic after one or more evidence-based treatments.(5) In OCD, there is usually the need to achieve the higher recommended doses of the medications, which may be associated with the occurrence of various side.”
Ocisková, M., Praško, J. P., Vaněk, J., Holubová, M., Hodný, F., Látalová, K., Kantor, K., & Nesnídal, V. (2021) · Psychology Research and Behavior Management · doi:10.2147/prbm.s287419 · Cited by 18
Online computer-aided vicarious exposure for OCD symptoms: A pilot study
Matthews, A. J., Maunder, R., Scanlan, J. D., & Kirkby, K. C. (2016) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2016.06.002 · Cited by 14
Andersson, E., Ljótsson, B., Hedman‐Lagerlöf, E., Mattson, S., Enander, J., Andersson, G., Kaldo, V., Lindefors, N., & Rück, C. (2014) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2014.10.002 · Cited by 12
Brakoulias, V., & Tsalamanios, E. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1250886 · Cited by 13
“Studies of effectiveness often focus on symptom reduction (defined as either a 25% or 35% reduction in OCD symptom severity measured by the Yale–Brown Obsessive– Compulsive Scale [Y–BOCS]) and even then, only 40–60% of sufferers achieve symptom reduction with SSRI treatment [3,4].”
MethodKim, H., Wheaton, M. G., Foa, E. B., & Simpson, H. B. (2022) · SSRN Electronic Journal · doi:10.1016/j.janxdis.2023.102711 · Cited by 11
Self-citationIkawa, H., Osawa, R., Sato, A., Mizuno, H., & Noda, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206133 · Cited by 10
“Furthermore, Laposa et al. noted that in CBT for OCD, a change in obsessions leads to a subsequent change in compulsions [15].”
BackgroundColes, M. E., Schubert, J. R., & Nota, J. A. (2021) · Behavior Therapy · doi:10.1016/j.beth.2021.02.006 · Cited by 10
Ameringen, M. V., Fineberg, N. A., Ravindran, A. V., Arnold, P. D., Beaulieu, S., Brakoulias, V., Brietzke, E. M., Dowlati, Y., Drummond, L. M., Ferretti, C. J., et al. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.12.039 · Cited by 14
Plasma fluvoxamine levels and OCD symptoms/response in adult patients
Marazziti, D., Baroni, S., Giannaccini, G., Piccinni, A., Picchetti, M., Massimetti, G., Schiavi, E., Palego, L., & Catena-Dell’Osso, M. (2012) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2240 · Cited by 9
“…believed that a 35%Y-BOCS reduction could be reasonably considered a full response (Pallanti et al., 2002), although the question is still open (Tolin et al., 2005; Simpson et al., 2006) in the present study, responders were defined as those showing a 35% decrease of the Y-BOCS total score.”
BackgroundGönner, S., Limbacher, K., & Ecker, W. (2012) · Verhaltenstherapie · doi:10.1159/000335776 · Cited by 12
Hui, H., Hong, A., Gao, J. J., Yu, J., & Wang, Z. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.01.027 · Cited by 15
Lu, L., Zhang, T., Gao, R., Zhang, Z., Cao, X., Chen, Y., Liu, Y., Zhang, F., Zheng, Y., Sun, Y., et al. (2018) · Journal of Health Psychology · doi:10.1177/1359105318780540 · Cited by 9
“12 ⩽ Y-BOCS score ⩽ 25 (Simpson et al., 2006).”
Chu, C., Lin, Y., Huang, C. C., Chung, Y., Park, S. Y., Chang, W., Chang, C.-C., & Chang, H. (2025) · Medicina · doi:10.3390/medicina61020169 · Cited by 11
“Around one-third of OCD patients fail to benefit significantly from first-line treatment, such as serotonin reuptake inhibitors (SSRIs) or cognitive behavioral therapy [2].”
Wang, P., Gu, W., Gao, J. J., Wang, C., Fang, J., Hu, M., Xiang, H., Li, B., Liu, N., Tang, W., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.822976 · Cited by 7
Self-citationWang, J., Hua, G., Wang, S., Guo, G., Quan, D., Yao, S., & Zheng, H. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.064 · Cited by 11
Grützmann, R., Klawohn, J., Elsner, B., Reuter, B., Kaufmann, C., Riesel, A., Bey, K., Heinzel, S., & Kathmann, N. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103216 · Cited by 6
Wheaton, M. G., Schwartz, M. R., Pascucci, O., & Simpson, H. B. (2015) · Psychiatric Annals · doi:10.3928/00485713-20150602-05 · Cited by 7
Self-citationIdentifying subgroups of urge suppression in Obsessive-Compulsive Disorder using machine learning
Eng, G. K., De Nadai, A. S., Collins, K. A., Recchia, N., Tobe, R. H., Bragdon, L. B., & Stern, E. R. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.06.052 · Cited by 6
van de Mortel, L. A., Bruin, W. B., Alonso, P., Bertolín, S., Feusner, J. D., Guo, J. Y., Hagen, K., Hansen, B. K. A., Thorsen, A. L., Martínez‐Zalacaín, I., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119729 · Cited by 7
N-acetylcysteine blocks serotonin 1B agonist-induced OCD-related behavior in mice.
Allen, E. M., Hughes, E. F., Anderson, C. J., & Woehrle, N. S. (2018) · Behavioral Neuroscience · doi:10.1037/bne0000251 · Cited by 7
Sarichloo, M. E., Taremian, F., Dolatshahee, B., & Javadi, S. A. H. S. (2020) · Iranian Journal of Psychiatry and Behavioral Sciences · doi:10.5812/ijpbs.101535 · Cited by 10
“Consistency exists between the results presented above and the findings of other studies that have emphasized the high dropout rate of patients with OCD treated with ERP (4, 5, 7, 9).”
BackgroundResultManaging obsessive compulsive disorder
Brakoulias, V. (2015) · Australian Prescriber · doi:10.18773/austprescr.2015.040 · Cited by 6
Chu, L., Wu, Y., Yin, J., Zhang, K., Zhong, Y., Fan, X., & Wang, G. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1350978 · Cited by 5
Bragdon, L. B., Nota, J. A., Eng, G. K., Recchia, N., Kravets, P., Collins, K. A., & Stern, E. R. (2023) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2023.100824 · Cited by 5
Toprak, T. B. (2024) · Spiritual Psychology and Counseling · doi:10.37898/spiritualpc.1319545 · Cited by 8
The Role of Neurophysiological Biomarkers in Obsessive-Compulsive Disorder
Herzog, S., & Brakoulias, V. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867329666211217094941 · Cited by 6
Speisman, B. B. (2012) · Digital Commons - University of South Florida (University of South Florida) · Cited by 7
Sheth, S. A., Provenza, N. R., Soubra, S. S., Hamre, T. A., Shofty, B., Banks, G. P., Giridharan, N., Momin, F., Vogt, G. S., McKay, S. A., et al. (2026) · medRxiv · doi:10.64898/2026.04.24.26351318 · Cited by 6
Ji, Y., Luo, Y., & Chen, R. (2025) · PRESENCE Virtual and Augmented Reality · doi:10.1162/pres_a_00443 · Cited by 3
Wright, J. H., Thase, M. E., & Beck, A. T. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615371501.lr33 · Cited by 4
Löchner, C., Naudé, P. J. W., & Stein, D. J. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230829145425 · Cited by 33
“…behavioral therapy, including exposure and response prevention (CBT/ERP), is efficacious for approximately half of the participants with OCD [10, 11], with non-response to treatment being associated with lack of adherence to treatment, poor insight, comorbid depression, and increased OCD…”
Merling, L. F., Siev, J., & Lit, K. R. (2018) · Current Psychology · doi:10.1007/s12144-018-0029-y · Cited by 4
Giordano, U., Mizera, J., Żak, E., Pilch, J., Tomecka, P., Dudzik, T., Palczewski, M., Biziorek, W., & Piotrowski, P. (2023) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_266_23 · Cited by 3
“[26–28] For individuals with severe forms of OCD that are resistant to traditional treatment methods, there are a number of noninvasive and invasive techniques that may offer relief.”
Jacoby, R. J., Greenberg, J. L., Hurtado, A. M., Pedersen, W. S., Ellard, K. K., Pace-Schott, E. F., Oliver, K. I., Milad, M. R., Wilhelm, S., & Camprodon, J. A. (2025) · Behaviour Research and Therapy · doi:10.1016/j.brat.2025.104858 · Cited by 3
Wheaton, M. G., Hagen, K., Björgvinsson, Þ., Kvale, G., & Hansen, B. K. A. (2024) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2024.100871 · Cited by 7
Response Versus Remission in Obsessive-Compulsive Disorder
Ballenger, J. C. (2007) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)70542-5 · Cited by 3
Kombinierte Pharmako- und Psychotherapie
Sachs, G., & Katschnig, H. (2010) · Springer eBooks · doi:10.1007/978-3-211-85473-0_20 · Cited by 3
Chapter 33. Cognitive-Behavioral Therapy
Wright, J. H., Thase, M. E., & Beck, A. T. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372980.lr33 · Cited by 3
Haft, S. M., Rauch, S. A. M., Rothbaum, B. O., & Sherrill, A. M. (2025) · Journal of Traumatic Stress · doi:10.1002/jts.70019 · Cited by 2
“ERP has demonstrated large effect sizes for decreases in OCD symptom severity ( g = .75; Ferrando & Selai, 2021) and a remission rate of approximately 50% (Simpson et al., 2006).”
Rector, N. A., Hawley, L. L., McCabe, R. E., Rowa, K., Key, B. L., Kassardjian, K., Richter, M. A., Sittampalam, S., & Shifrin, A. (2026) · Cognitive Therapy and Research · doi:10.1007/s10608-025-10669-z · Cited by 3
Bai, T., Wang, Y., Ruan, H., Zhang, G., Gao, J., Zheng, Z., Li, D., Zhao, Q., Han, H., Fan, Q., et al. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02375-5 · Cited by 2
“However, only approximately half of patients respond to fi rst-line pharmacological strategies [6] — selective serotonin reuptake inhibitors (SSRIs) [7], and reliance on post hoc identi fi cation through sequential medication trials delays effective intervention and exacerbates disability burden.”
Defining Treatment Response and Remission in Obsessive-Compulsive Disorder
Storch, E. A., Lewin, A. B., Nadai, A. S. D., & Murphy, T. K. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-201007000-00011 · Cited by 2
The efficacy of brief strategic therapy in treating obsessive-compulsive disorder: a case series.
Proietti, L., Aguglia, A., Amerio, A., Costanza, A., Fesce, F., Magnani, L., Serafini, G., & Amore, M. (2022) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v93is1.13064 · Cited by 7
“%) is than that observed in other studies (14,15,40).”
ResultWheaton, M. G. (2025) · CBT: science into practice · doi:10.1007/978-3-031-91439-3_14 · Cited by 2
Lai, J., Zhou, W., Lu, Q., Huang, T., Xu, Y., & Hu, S. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s151396 · Cited by 2
“patients achieved remission following SSRI treatment.(10) In addition, antipsychotics have been recently recognized as augmentation strategies in SSRI-refractory OCD patients.”
InfluentialThe Affect Of Religious Cognitive-Behavior Therapy On Quality Of Life Obsessive –Compulsive Disorder
Almasi, A., Akuchekian, S., Nabi, L. N., Emranifard, V., & Najafi, M. (2015) · International Journal of Behavioral Research & Psychology · doi:10.19070/2332-3000-1500013 · Cited by 2
“By encouraging resistance to symptoms during anxiety-provoking situations [17].”
BackgroundRelapse of obsessive–compulsive disorder after cerebral venous sinus thrombosis: a case report
Velikić, V., Wippel, A., & Freidl, M. (2019) · Neuropsychiatrie · doi:10.1007/s40211-019-00327-8 · Cited by 3
Sarangi, A., Payberah, D., & McMahon, T. C. (2021) · Cureus · doi:10.7759/cureus.14920 · Cited by 3
“Despite the documented benefits of the established treatments for OCD, the disease remains difficult to manage [1,8], with one study claiming that 30-40% of patients show poor response to modern treatments [7], and another showing that half of the patients with OCD do not fully respond to treatment [1].”
BackgroundÖzen, M. E., Kalenderoğlu, A., Çelik, M., Örüm, M. H., & Hocaoğlu, Ç. (2019) · Adıyaman Üniversitesi Sağlık Bilimleri Dergisi · doi:10.30569/adiyamansaglik.477617 · Cited by 5
Huang, X., Xiao, L., Wang, M., Wu, Y., Deng, H., & Wang, W. (2025) · Brain Sciences · doi:10.3390/brainsci15010043 · Cited by 1
Qiu, H., Zhao, Y., Liu, C., Li, Y., Li, Y., & Zhu, H. (2026) · Brain-Apparatus Communication A Journal of Bacomics · doi:10.1080/27706710.2025.2610827 · Cited by 1
Restifo-Bernstein, G., Guo, J., Kegeles, L. S., Shungu, D. C., & Simpson, H. B. (2026) · Journal of Mood and Anxiety Disorders · doi:10.1016/j.xjmad.2026.100168 · Cited by 2
“First-line treatments for OCD — serotonin reuptake inhibitors (SRIs) and cognitive behavioral therapy (CBT) — are effective but only lead to remission in some patients [2]; yet regaining function and quality of life requires remission [3].”
Self-citationLópez-Rodríguez, S., Segalàs, C., Real, E., Urretavizcaya, M., Bertolín, S., Menchón, J. M., & Alonso, M. D. P. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-08119-5 · Cited by 1
“For OCD, response was defined a priori as a ≥ 35% reduction from baseline Y-BOCS, in line with commonly used criteria for clinically meaningful treatment response in OCD studies [27, 28].”
Metadata
- Authors
- Simpson, H. B., Huppert, J. D., Petkova, E., Foa, E. B., & Liebowitz, M. R.
- Affiliations
- New York State Psychiatric Institute (US)
- University of Pennsylvania (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2006-02-15
- Volume
- 67
- Issue
- 02
- Pages
- 269-276
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2011811397
- Cited by
- 241
- References
- 0
- Citations by year
- 2026: 13 · 2025: 11 · 2024: 8 · 2023: 7 · 2022: 14 · 2021: 21 · 2020: 8 · 2019: 17 · 2018: 12 · 2017: 12 · 2016: 13 · 2015: 15 · 2014: 11 · 2013: 15 · 2012: 15
- FWCI
- 11.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (R01MH045404, R01MH-45404, K23MH001907, MH01907, R01MH045436, R01MH-45436)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- obsessive-compulsive disorder, treatment response, remission, exposure and response prevention, clomipramine, combination therapy, Yale-Brown Obsessive Compulsive Scale, comorbid depression, adults
- MeSH terms
- Adult, Ambulatory Care, Antidepressive Agents, Tricyclic, Clomipramine, Combined Modality Therapy, Female, Humans, Male, Terminology as Topic, Obsessive-Compulsive Disorder, Placebos, Psychiatric Status Rating Scales, Psychometrics, Cognitive Behavioral Therapy, Treatment Outcome, Outcome Assessment, Health Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.